Wednesday, June 10, 2026

Drug profile · INN

methazolamide

methazolamide (METHAZOLAMIDE) is a carbonic anhydrase iv inhibitor. Route of administration: oral. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — methazolamide
US status
approved
Class
Route
ORAL
Patents
0
Programs
0
Data quality
0.84

Quick answer

methazolamide (METHAZOLAMIDE) is a carbonic anhydrase iv inhibitor. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN methazolamide
Brand METHAZOLAMIDE
Mechanism Carbonic anhydrase IV inhibitor
Target Carbonic anhydrase 1
Route ORAL
Formulation TABLET

Mechanism of action

Carbonic anhydrase IV inhibitor

Primary target: Carbonic anhydrase 1

Approval history

Authority Status Date
FDA approved

Related & competitor drugs

  1. acetazolamide Carbonic anhydrase XII inhibitor
  2. acetazolamide sodium Carbonic anhydrase XII inhibitor
  3. dichlorphenamide Carbonic anhydrase XII inhibitor
  4. methocarbamol Carbonic anhydrase I inhibitor
  5. diclofenamide Sensory organs (S01)

Frequently asked questions

What is methazolamide?

methazolamide (METHAZOLAMIDE) is a carbonic anhydrase iv inhibitor. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for methazolamide?

METHAZOLAMIDE is a marketed brand name for methazolamide. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of methazolamide?

methazolamide has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.